PFIZER INC(PFE)— Stock Profile, AI Score & Financials
Healthcare · NYSE · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .
PFIZER INC (PFE) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores PFE at 62.0/100 on a 32-signal composite quality model, placing it at rank #735 of 2,961 stocks — the top 25% of the AI-ranked universe. PFE scores in the top quartile across revenue scale (97.5), earnings quality (90.6). Areas of concern include profitability (39.4), which score below median versus the broader universe. Based on the latest XBRL financial filings (Q2 2026), PFIZER INC reports quarterly revenue of $15.0B, net income of $-248.0M, free cash flow of $302.0M. Top institutional holders of PFE by reported 13-F value include BlackRock, VANGUARD CAPITAL MANAGEMENT, STATE STREET, based on the most recent SEC filings. PFE trades on the NYSE exchange and files with the SEC under CIK 78003. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate PFE daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for PFIZER INC directly from SEC EDGAR.
AI Quality Score
62.0/100
AI Rank
#735
Revenue
$15.0B
Net Income
$-248.0M
Free Cash Flow
$302.0M
PFE key financials by period
PFIZER INC reported revenue, net income and margins by fiscal period, from SEC filings.
Period
Form
Revenue
Net income
Operating margin
FY 2025
10-K
$62.6B
$7.8B
12.0%
FY 2024
10-K
$63.6B
$8.0B
12.6%
FY 2023
10-K
$59.6B
$2.1B
1.8%
FY 2022
10-K
$101.2B
$31.4B
34.3%
FY 2021
10-K
$81.3B
$22.0B
29.9%
FY 2020
10-K
$41.7B
$9.2B
16.9%
Institutions holding PFE
Institutional investors reporting a position in PFIZER INC on SEC Form 13F.
AI-extracted from the 10-Q filed 2026-08-04 — Q2 2026 (quarter ended June 28, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.
Revenue rose 3% to $15.0B, but $4.3B of intangible asset impairments drove a $248M net loss versus $2,910M net income a year earlier.
Biggest Revenue Drivers
Primary Care$5,503M
Eliquis, Nurtec ODT/Vydura and Abrysvo growth offset by declines in Comirnaty, Paxlovid and the Prevnar family
Oncology$4,165M
Padcev up on first-line la/mUC market share and Lorbrena up on first-line ALK+ NSCLC patient share; Adcetris and Bosulif declined
Biggest Revenue Drivers
Total revenue: $15.0B+3% YoY
Primary Care$5,503M
Eliquis, Nurtec ODT/Vydura and Abrysvo growth offset by declines in Comirnaty, Paxlovid and the Prevnar family
Within Primary Care
Eliquis$2,425M+21% YoY
Higher U.S. net price from pricing dynamics including lower rebates and channel mix favorability, plus higher demand globally
Oncology$4,165M
Padcev up on first-line la/mUC market share and Lorbrena up on first-line ALK+ NSCLC patient share; Adcetris and Bosulif declined
Specialty Care$3,353M
Vyndaqel family growth from U.S. market expansion and international demand, partly offset by Xeljanz decline
Hospital and Biosimilars$1,640M
Inflectra and oncology biosimilars growth offset by declines in Sulperazon and Zithromax
Largest Expense Items
Cost of sales$4,092M+8% YoY
$130M unfavorable sales mix, $90M higher amortization of acquired inventory step-up driven by the Oxbryta impairment, $60M FX
Other (income)/deductions—net$3,716M
$4.3B intangible impairments and $842M legal charges, partly offset by a $1.870B net gain on the ViiV investment sale
Selling, informational and administrative$3,411Mflat YoY
$70M lower corporate enabling function spend offset by $40M higher cost-realignment implementation costs and $35M unfavorable FX
Research and development$2,809M+13% YoY
Anticipated $240M increase in spending on certain oncology and obesity product candidates
Margins: Cost of sales rose to 27.2% of revenues from 25.8%, driven by unfavorable sales mix and higher amortization of the fair value step-up of acquired inventory tied to the Oxbryta impairment. Management calls long-term gross margin improvement a key focus.
Watch Items from the Filing
$4.3B of impairments: $3.8B IPR&D for sigvotatug vedotin after the Phase 3 SigVie-002 study missed its overall survival endpoint, and $525M for Oxbryta.
COVID franchise collapsed: Paxlovid revenue fell 95% to $21M and Comirnaty fell 32% to $261M; excluding both, revenue grew 5% operationally.
Pfizer expects roughly $1.1 billion of unfavorable 2026 revenue impact from patent or regulatory exclusivity expiries, with the rate of decline accelerating through 2030.
New restructuring phases add ~$4.0B (manufacturing) and ~$2.0B (cost base) of one-time costs through 2029 against ~$1.5B and ~$1.0B of expected savings.
Under binding agreements with the U.S. Government, the Section 232 pharmaceutical tariff rate for Pfizer products is zero until January 20, 2029.
AI-extracted and verified against SEC EDGAR filing text. Not investment advice.
